[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4667 Introduced in House (IH)]

<DOC>






116th CONGRESS
  1st Session
                                H. R. 4667

  To amend the 21st Century Cures Act to reauthorize funding for NIH 
              innovation projects, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            October 11, 2019

Ms. Sherrill (for herself, Mr. Levin of California, and Ms. Spanberger) 
 introduced the following bill; which was referred to the Committee on 
                          Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
  To amend the 21st Century Cures Act to reauthorize funding for NIH 
              innovation projects, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Biomedical Innovation Expansion Act 
of 2019''.

SEC. 2. REAUTHORIZATION OF NIH INNOVATION PROJECTS.

    (a) Transfers.--Section 1001(b)(2)(A) of the 21st Century Cures Act 
(Public Law 114-255) is amended by striking clauses (v) through (x) and 
inserting the following:
                            ``(v) For fiscal year 2021, $854,000,000.
                            ``(vi) For fiscal year 2022, 
                        $1,051,000,000.
                            ``(vii) For fiscal year 2023, 
                        $1,345,000,000.
                            ``(viii) For fiscal year 2024, 
                        $1,271,000,000.
                            ``(ix) For fiscal year 2025, 
                        $1,301,000,000.
                            ``(x) For fiscal year 2026, $1,306,000,000.
                            ``(xi) For fiscal year 2027, 
                        $1,336,000,000.
                            ``(xii) For fiscal year 2028, 
                        $1,376,000,000.
                            ``(xiii) For fiscal year 2029, 
                        $1,436,000,000.
                            ``(xiv) For fiscal year 2030, 
                        $1,469,000,000.''.
    (b) Authorization of Appropriations.--Section 1001(b)(3)(A) of the 
21st Century Cures Act (Public Law 114-255) is amended by striking 
``2026'' and inserting ``2030''.
    (c) Offsetting Future Appropriations.--Section 1001(b)(3)(B) of the 
21st Century Cures Act (Public Law 114-255) is amended by striking 
``2026'' and inserting ``2030''.
    (d) NIH Innovation Projects.--Section 1001(b)(4) of the 21st 
Century Cures Act (Public Law 114-255) is amended--
            (1) in the matter preceding subparagraph (A), by striking 
        ``2026'' and inserting ``2030'';
            (2) in subparagraph (A)--
                    (A) in the matter preceding clause (i), by striking 
                ``$1,455,000,000'' and inserting ``$4,413,000,000''; 
                and
                    (B) by striking clauses (v) through (x) and 
                inserting the following:
                            ``(v) For fiscal year 2021, $209,000,000.
                            ``(vi) For fiscal year 2022, $300,000,000.
                            ``(vii) For fiscal year 2023, $419,000,000.
                            ``(viii) For each fiscal years 2024 through 
                        2030, $430,000,000.'';
            (3) in subparagraph (B)--
                    (A) in the matter preceding clause (i), by striking 
                ``$1,511,000,000'' and inserting ``$4,428,000,000''; 
                and
                    (B) by striking clauses (v) through (x) and 
                inserting the following:
                            ``(v) For fiscal year 2021, $250,000,000.
                            ``(vi) For fiscal year 2022, $302,000,000.
                            ``(vii) For fiscal year 2023, $450,000,000.
                            ``(viii) For each of fiscal years 2024, 
                        2025, and 2026, $400,000,000.
                            ``(ix) For fiscal year 2027, $425,000,000.
                            ``(x) For fiscal years 2028, $450,000,000.
                            ``(xi) For each of fiscal years 2029 and 
                        2030, $500,000,000.'';
            (4) in subparagraph (C)--
                    (A) in the matter preceding clause (i), by striking 
                ``$1,800,000,000'' and inserting ``$3,312,000,000''; 
                and
                    (B) by amending clause (vii) to read as follows:
                            ``(vii) For each of fiscal years 2023 
                        through 2030, $216,000,000.'';
            (5) in subparagraph (D)--
                    (A) in the matter preceding clause (i), by striking 
                ``$30,000,000'' and inserting ``$250,000,000''; and
                    (B) by striking clause (iv) and inserting the 
                following:
                            ``(iv) For each of fiscal years 2021, 2022, 
                        and 2023, $50,000,000.
                            ``(v) For each of fiscal years 2024 through 
                        2030, $10,000,000.''; and
            (6) by adding at the end the following:
                    ``(E) To support research related to combating 
                antimicrobial resistance and antibiotic resistant 
                bacteria, not to exceed a total of $1,635,000,000, as 
                follows:
                            ``(i) For fiscal year 2021, $100,000,000.
                            ``(ii) For each of fiscal years 2022 
                        through 2024, $150,000,000.
                            ``(iii) For each of fiscal years 2025 
                        through 2027, $175,000,000.
                            ``(iv) For each of fiscal years 2028 and 
                        2029, $180,000,000.
                            ``(v) For fiscal year 2030, $200,000,000.
                    ``(F) To support research and research activities 
                related to rare diseases or conditions, not to exceed a 
                total of $758,000,000, as follows:
                            ``(i) For fiscal year 2021, $50,000,000.
                            ``(ii) For fiscal year 2022, $55,000,000.
                            ``(iii) For fiscal year 2023, $60,000,000.
                            ``(iv) For fiscal year 2024, $65,000,000.
                            ``(v) For fiscal year 2025, $70,000,000.
                            ``(vi) For fiscal year 2026, $75,000,000.
                            ``(vii) For fiscal year 2027, $80,000,000.
                            ``(viii) For fiscal year 2028, $90,000,000.
                            ``(ix) For fiscal year 2029, $100,000,000.
                            ``(x) For fiscal year 2030, 
                        $113,000,000.''.
    (e) Workplan.--Section 1001(c)(1)(A) of the 21st Century Cures Act 
(Public Law 114-255) is amended by striking ``2026'' and inserting 
``2030''.
    (f) Recommendations.--Section 1001(c)(1)(C)(i) of the 21st Century 
Cures Act (Public Law 114-255) is amended by striking ``2026'' and 
inserting ``2030''.
    (g) Annual Reports.--Section 1001(c)(2)(A) of the 21st Century 
Cures Act (Public Law 114-255) is amended by striking ``2027'' and 
inserting ``2030''.
    (h) Sunset.--Section 1001(e) of the 21st Century Cures Act (Public 
Law 114-255) is amended by striking ``September 30, 2026'' and 
inserting ``September 30, 2030''.
                                 <all>